OncoLens Welcomes Cross Border Impact Venture Fund as Capital Partner to Fuel International Growth

ATLANTA (PRWEB) JULY 13, 2023

OncoLens  provides an integration and collaboration platform to cancer centers, helping derive intelligence from swaths of disparate structured and unstructured data to empower centers to identify patients for clinical trials, research, biomarker testing and more. Insights derived are funneled into collaboration workflows and matched with clinical decision support to assist often siloed multi-disciplinary teams to determine the best plan forward for the patient.

With the investment and partnership from  Cross Border , OncoLens plans to expand its domestic and global footprint into regions including rural communities and low-middle income countries where there are needs to add capacity, resources and access to shared expertise to identify the right diagnostics and treatments for patients, as well as support much needed diversity and inclusion in access and research.

With more than 200 cancer centers in the U.S and clients in the larger EMEA (Europe, Middle East and Africa) region, OncoLens’ network enables cross collaboration between multiple entities whether they are academic center/NCIs (national cancer institutes) and their community affiliates, large integrated delivery networks (IDNs) or across international borders. “With this new investment from Cross Border, we are excited to align our existing and future clients to international collaboration, improved patient care, and revenue opportunities,” says Anju Mathew, CEO of OncoLens.

“With an established network, OncoLens is on the cusp of creating an unprecedented global network of oncology providers that will open up access to cutting edge solutions for patients, enable global collaboration and intelligence sharing across the oncology ecosystem. We look forward to participating on this journey with the OncoLens team,” says Donna Parr, managing director and partner at Cross Border Impact Ventures.

ABOUT ONCOLENS

OncoLens enables multidisciplinary cancer care across the continuum. Through a streamlined, secure HIPAA-compliant infrastructure, OncoLens drives intra-enterprise, community, and network participation in multidisciplinary care planning, tracking, and delivery. Using OncoLens, cancer care providers view a singular view of the patient including outpatient and in-patient clinical data, pathology, radiology, genomics and genetic information. They can collaborate on treatment plans, track quality for accreditation, and alignment to care pathways. As a result, health systems maximize clinical trial participation, an extended referral stream, and the creation of a center of excellence that can be leveraged to support patient care and provider education.  http://www.oncolens.com

ABOUT CROSS BORDER IMPACT VENTURES

Cross-Border Impact Ventures is an impact venture capital firm on a mission to revolutionize venture capital investing in health technology. We invest in early growth stage health technology companies relevant to women, children and adolescent health and located in North America, Europe and Israel with ability to scale technologies to Emerging Markets. We seek to expand access to world class technologies inclusively and globally because good health should not be restricted by gender, age, race, wealth and borders.  http://www.crossborder.ventures

CONTACT

OncoLens: info@oncolens.com

GLS 2025 Year in Review

December 22, 2025
Dear Georgia Life Sciences Community, As we reflect on the past year, I want to extend my sincere thanks to our Georgia Life Sciences members for making it such an impactful one. Your engagement and leadership continue to move our industry forward and advance our shared strategic priorities— driving strong policy, expanding the talent pipeline, and creating intentional spaces for collaboration across Georgia’s life sciences ecosystem. Our Year in Review captures the progress we’ve made together across these priorities and highlights the collective impact our members are having statewide—from strengthening the workforce and supporting manufacturing growth to elevating Georgia’s position as a national life sciences leader. This progress is only possible because of the collaboration, commitment, and insight of our member community. 

Investing in America’s Biopharmaceutical Infrastructure Strengthens the Economy and Supports Union Workers

By Maria Thacker Goethe • December 20, 2025
The biopharmaceutical industry is growing America’s manufacturing and R&D capabilities to develop the next generation of treatments. A recent study from PILMA quantified the impact of the industry’s investment in American infrastructure on the economy and union workforce across 18 states from 2019-2024. The study found that across the 18 states included, the biopharmaceutical industry: Supported the American economy by investing $86.5B in R&D and manufacturing infrastructure and developing 1000+ construction projects at over 700 distinct facilities. Strengthened the American workforce by generating $2.6B in skilled union wages and providing $19M in support for union apprenticeships. The impact of the biopharmaceutical industry’s investment in American manufacturing and union jobs extends beyond direct benefits, spurring additional economic activity in the communities where workers live. This is known as the multiplier effect . On average, every $1 of new investment in a U.S. biopharmaceutical manufacturing facilities generates an additional $1.59 in further economic activity (2.59x times the initial investment value). The industry’s $86.5B investment in R&D and manufacturing infrastructure has a total economic impact of $224B. Check out this resource to learn more about how biopharmaceutical investment in American infrastructure supports America’s workers and communities. For more on how biopharmaceutical companies are investing in America’s future, visit innovation.org/america-investment .

Georgia Life Sciences Joins National Coalition Urging Congressional Action on Key Innovation Policies

December 10, 2025
Georgia Life Sciences has joined 43 state and regional life sciences organizations in signing a national Council of State Bioscience Associations (CSBA) letter calling on Congress to take immediate action on three bipartisan policy priorities that are essential to sustaining U.S. leadership in biomedical innovation and supporting patients nationwide. With Congress back in session and several critical programs at risk of expiring, the letter urges congressional leaders to advance the following provisions without delay: 1. Reauthorize the Rare Pediatric Disease Priority Review Voucher (PPRV) Program The PPRV program has been instrumental in incentivizing the development of therapies for children with rare and life-threatening conditions. Its lapse threatens to slow or halt research that families across the country are counting on. 2. Extend the SBIR/STTR Programs The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs provide crucial early-stage capital for emerging biotech and medtech companies—many of them in Georgia. Without reauthorization, hundreds of innovative small businesses face uncertainty, jeopardizing new therapies, diagnostics, and technologies in the pipeline, 3. Advance PBM Transparency Reforms Greater transparency and accountability within pharmacy benefit manager (PBM) practices are needed to ensure that savings reach patients and employers. Reforming PBM operations is essential to strengthening access and affordability across the healthcare system. A Unified Message from the Life Sciences Community The sign-on letter reflects broad, bipartisan alignment across the national life sciences ecosystem: researchers, entrepreneurs, investors, patient advocates, and state associations all share a common message— these programs underpin America’s global competitiveness and are vital to patients who rely on continued scientific progress. Georgia Life Sciences has shared the letter with members of Georgia’s congressional delegation and will continue engaging with policymakers to emphasize the importance of swift action.
MORE POSTS